Introduction {#jcmm12806-sec-0001}
============

Atopic dermatitis (AD) is one of the most common inflammatory skin conditions, predominantly affecting infants and children. It is characterized by pruritus, eczematous lesions and skin dryness. Atopic dermatitis is a complex chronic relapsing inflammatory skin disorder involving immune hyper‐responsiveness of the skin, epidermal barrier abnormalities, genetic susceptibility and environmental factors [1](#jcmm12806-bib-0001){ref-type="ref"}. In its acute phase, AD is characterized by an abnormal production of thymic stromal lymphopoietin (TSLP), an alarmin secreted by keratinocytes and leading to expansion of Th2 cells *via* activation of Langerhans cells (LCs) [2](#jcmm12806-bib-0002){ref-type="ref"}, [3](#jcmm12806-bib-0003){ref-type="ref"}, [4](#jcmm12806-bib-0004){ref-type="ref"}. Moreover, interleukin (IL)‐17 has been shown to be present in acute AD [5](#jcmm12806-bib-0005){ref-type="ref"}. A Th1/Th22 predominant immune response, dermal infiltration with inflammatory dendritic epidermal cells (IDECs), macrophages and eosinophils as well as bacterial superinfection are classical features of the chronic phase of AD [2](#jcmm12806-bib-0002){ref-type="ref"}.

Regulatory T cells (T~regs~) play a critical role in the maintenance of peripheral tolerance and in the control of allergic responses. Despite a growing interest in the role of T~regs~ in the pathogenesis of AD, their precise role remains unclear. In both humans and mice, loss‐of‐function mutations in the FoxP3 gene lead to a multiorgan inflammatory response including skin inflammation resembling AD associated with elevated serum IgE levels, eosinophilia, allergic airway inflammation, food allergies and other autoimmune symptoms [6](#jcmm12806-bib-0006){ref-type="ref"}, [7](#jcmm12806-bib-0007){ref-type="ref"}. These data suggest that lack of functional T~regs~ is sufficient to recapitulate important immunologic features of AD. Accordingly, lower circulating T~regs~ at birth and lower T~reg~ numbers in cord blood predict a higher risk for the development of AD in the first year of life [8](#jcmm12806-bib-0008){ref-type="ref"}. Furthermore, analysis of thymic tissue from atopic children revealed significantly delayed maturation of thymic T~regs~ as compared to age‐matched, non‐atopic controls [9](#jcmm12806-bib-0009){ref-type="ref"}. However, studies in adults seem to dismiss this hypothesis. Some authors reported equal levels of circulating T~regs~ [10](#jcmm12806-bib-0010){ref-type="ref"}, [11](#jcmm12806-bib-0011){ref-type="ref"}, [12](#jcmm12806-bib-0012){ref-type="ref"}, whereas others found increased circulating T~regs~, directly correlating with AD disease severity in patients with persisting AD in adulthood as compared to healthy controls [13](#jcmm12806-bib-0013){ref-type="ref"}, [14](#jcmm12806-bib-0014){ref-type="ref"}, [15](#jcmm12806-bib-0015){ref-type="ref"}, [16](#jcmm12806-bib-0016){ref-type="ref"}. Furthermore, there are conflicting reports about the presence of T~regs~ in inflammatory infiltrates of AD skin [10](#jcmm12806-bib-0010){ref-type="ref"}, [17](#jcmm12806-bib-0017){ref-type="ref"}, [18](#jcmm12806-bib-0018){ref-type="ref"}, and controversy exists about the immune suppressive capacity of T~regs~ in AD. T~regs~ from AD patients were shown to exhibit normal suppressive activity at baseline [11](#jcmm12806-bib-0011){ref-type="ref"}, [15](#jcmm12806-bib-0015){ref-type="ref"} or after allergen‐stimulation [19](#jcmm12806-bib-0019){ref-type="ref"}, but T~regs~ exhibiting reduced suppressive function have also been identified in patients with AD [13](#jcmm12806-bib-0013){ref-type="ref"}. Intriguingly, stimulation with staphylococcal superantigen (staphylococcal enterotoxin B) leads to a Th2‐dominated cytokine profile in circulating CCR6^−^ T~regs~ of AD patients [12](#jcmm12806-bib-0012){ref-type="ref"}, [14](#jcmm12806-bib-0014){ref-type="ref"} and there is emerging evidence that T~regs~ can convert to Th2 cells, thereby contributing to AD instead of dampening the immune response [20](#jcmm12806-bib-0020){ref-type="ref"}.

Because the T~reg~ population remains poorly characterized in AD, we here studied the phenotype and the dynamics of thymus‐derived *versus* peripherally derived T~regs~. Dendritic cells (DCs) are professional antigen‐presenting cells and key players in regulating immunity and tolerance, including the instruction of T~regs~. In light of the association of LCs with AD, we also investigated the role of skin‐derived DCs in activating these cells.

Materials and methods {#jcmm12806-sec-0002}
=====================

Animals {#jcmm12806-sec-0003}
-------

Mice of inbred Balb/c and C57BL/6 strains were purchased from Charles River Laboratories (Sulzfeld, Germany). Mice expressing a diphtheria toxin receptor (DTR) under the control of the Langerin (CD207) gene were bred on a C57BL/6 background as described earlier [21](#jcmm12806-bib-0021){ref-type="ref"}. All mice were used at 2--4 months of age and animal experiments were carried out according to governmental guidelines.

Mouse treatments {#jcmm12806-sec-0004}
----------------

1α,25‐dihydroxyvitamin D~3~ (1 nmol/ear) was dissolved in ethanol. Vehicle (ethanol) or vitamin D3 (VitD) were topically applied once daily onto inner and outer surfaces of mouse ears (10 μl/ear side) over a time period of 10 days (4 days treatment, 3 days no treatment, 3 days treatment) as described earlier [22](#jcmm12806-bib-0022){ref-type="ref"}. Diphtheria toxin in PBS or PBS alone was injected intraperitoneally into Langerin‐DTR mice on day −2 (1 μg/mouse), day +2 (100 ng/mouse), day +6 (100 ng/mouse) and day +8 (100 ng/mouse).

Antibodies and reagents {#jcmm12806-sec-0005}
-----------------------

Directly labelled primary monoclonal antibodies (mAb) specific for mouse CD4, CD25, inducible T‐cell costimulator (ICOS), CD11c, CCR7, IL‐10 and MHCII were purchased from BD Biosciences (San Diego, CA, USA), and for detection of mouse CCR7, PD‐L1, ICOS L, GITR L, CD11c, Glycoprotein‐A repetitions predominant receptor (GARP) and IL‐13 from eBioscience (San Diego, CA, USA). Directly labelled mAb for detection of cytotoxic T‐lymphocyte antigen (CTLA)‐4 was purchased from Biolegend (San Diego, CA, USA). For intracellular staining with anti‐mouse mAb against FoxP3 (eBioscience) and anti‐mouse mAb against Helios (Biolegend) cells were permeabilized and stained according to the manufacturer\'s instructions. Cell viability was assessed by LIVE/DEAD Fixable Dead Cell Stain Kit (Invitrogen, Carlsbad, CA, USA) or Fixable Viability Dye (eBioscience). Biotinylated mAb against mouse CD103 and CD25 were purchased from BD‐Biosciences, streptavidin PerCP Cy5.5 from Biolegend, and streptavidin APC from BD Biosciences. Directly labelled mAb against mouse Langerin (clone 929F.3) was purchased from Dendritics (Lyon, France) and used after permeabilization with Cytofix/Cytoperm kit (BD Biosciences), according to the manufacturer\'s instruction. Purified mAb against IDO was purchased from Biolegend and detected with directly conjugated goat anti‐rat immunoglobulin from BD Biosciences. 1α,25‐dihydroxyvitamin D~3~ and DT were purchased from Sigma‐Aldrich (St Louis, MO, USA).

Analysis of DCs and lymphocytes in skin‐draining lymph nodes of mice {#jcmm12806-sec-0006}
--------------------------------------------------------------------

Auricular skin‐draining lymph nodes (sdLNs) were collected from mice treated with VitD or vehicle on their ears and digested with collagenase D (Roche Diagnostics, Indianapolis, IN, USA) and DNase (Roche Diagnostics) for 25 min. at 37°C. Resulting single cell suspensions were counted in the haemocytometer, stained with mAb and analysed using flow cytometry as previously described [4](#jcmm12806-bib-0004){ref-type="ref"}. Absolute cell numbers per auricular draining lymph node (LN) were calculated on the basis of flow cytometry analysis and haemacytometer cell counts. Mouse T~regs~ were identified by expression of CD4, CD25 and FoxP3, and distinction between induced and natural T~regs~ was made on the basis of Helios staining. CD11c^+^ CCR7^+^ cells in sdLNs were considered as emigrated DCs. Expression of CD103 was used to discriminate epidermal LCs (CD11c^+^ CCR7^+^ CD103^−^ Langerin^+^) from Langerin^+^ dermal DCs (CD11c^+^ CCR7^+^ CD103^+^ Langerin^+^). CD11c^+^ CCR7^+^ CD103^+/−^ Langerin^−^ cells were considered as Langerin^−^ dermal DCs and CD11c^+^ CCR7^−^ CD103^+/−^ Langerin^−^ cells as 'other DC'.

Detection of intracellular cytokines {#jcmm12806-sec-0007}
------------------------------------

Isolated LN cells were cultured for 4 hrs with 1 μg/ml brefeldin A to block cytokine release; then stained and analysed by flow cytometry.

Flow cytometry and immunohistochemistry {#jcmm12806-sec-0008}
---------------------------------------

Flow cytometry analysis was performed on a FACScalibur using CellQuest software (BD Immunocytometry Systems, San Jose, CA, USA) and results were analysed by FlowJo software (Tree Star, Ashland, OR, USA). Five‐ and six‐colour stainings were carried out with a FACScanto using FACSDiva software (BD Immunocytometry Systems). Epidermal sheets were separated from ear skin with 0.5 M ammonium thiocyanate (Merck, Westchester, PA, USA) as described previously [4](#jcmm12806-bib-0004){ref-type="ref"}, washed and stained with antimouse MHC‐class II‐FITC mAb for 1 hr at 37°C. Stainings were visualized by an Olympus BX60 epifluorescence microscope using a 40× objective. Fluorochrome‐ and isotype‐matched immunoglobulins of irrelevant specificity served as negative controls.

Statistical analysis {#jcmm12806-sec-0009}
--------------------

Results are shown as mean ± SD, *n* represents the number of mice used per group. Data were analysed using a Student\'s *t*‐test for normally distributed values or a Mann--Whitney *U*‐test, when values did not show a Gaussian distribution or when *n* \< 5.

Results {#jcmm12806-sec-0010}
=======

AD‐like inflammation is associated with increased numbers of T~regs~ {#jcmm12806-sec-0011}
--------------------------------------------------------------------

To study T~regs~ in AD, we topically treated mice with VitD to trigger high TSLP expression in the epidermis as observed in AD lesions [4](#jcmm12806-bib-0004){ref-type="ref"}, [22](#jcmm12806-bib-0022){ref-type="ref"}. The inflammatory phenotype in these mice is similar to that observed in other TSLP‐overexpressing mice and is characterized by an AD‐like cutaneous inflammation containing Th2 CD4^+^ T cells expressing cutaneous homing receptors and by elevated serum IgE levels [4](#jcmm12806-bib-0004){ref-type="ref"}, [22](#jcmm12806-bib-0022){ref-type="ref"}, [23](#jcmm12806-bib-0023){ref-type="ref"}, [24](#jcmm12806-bib-0024){ref-type="ref"}, [25](#jcmm12806-bib-0025){ref-type="ref"}. Figure [1](#jcmm12806-fig-0001){ref-type="fig"} depicts the kinetic of T~reg~ (CD4^+^ CD25^+^ FoxP3^+^) and non‐regulatory (CD4^+^ CD25^+/−^ FoxP3^−^) CD4^+^ cell expansion in sdLNs of mice upon treatments. Results show that VitD treatment significantly enhanced numbers of T~regs~ at all time‐points when compared to vehicle treatment (Fig. [1](#jcmm12806-fig-0001){ref-type="fig"}A). In contrast, numbers of other CD4^+^ lymphocytes increased on days 3 and 5 but not on day 10 in sdLNs of VitD‐treated mice when compared to controls (Fig. [1](#jcmm12806-fig-0001){ref-type="fig"}B). Maximal cell numbers were reached for both subsets on day 5 (Fig. [1](#jcmm12806-fig-0001){ref-type="fig"}A and B). Thus, although the expansion of T~regs~ was continuously promoted by VitD, the expansion of other CD4^+^ lymphocytes regressed between day 5 and day 10 (Fig. [1](#jcmm12806-fig-0001){ref-type="fig"}A and B). The variations in cell percentages (Fig. [1](#jcmm12806-fig-0001){ref-type="fig"}C and D) with decreased percentages of T~regs~ on day 3 and decreased percentages of other CD4^+^ lymphocytes on day 10 additionally suggest that the expansion of non‐regulatory CD4^+^ lymphocytes precedes the expansion of T~regs~. Because AD‐like symptoms in mice treated with VitD enhance over time, our data show that expansion of T~regs~ parallels symptom development in this AD model.

![Regulatory T cells are increased in murine AD‐like inflammation. Numbers (**A** and **B**) and percentages (**C** and **D**) of CD4^+^ CD25^+^ FoxP3^+^ T~regs~ and CD4^+^ CD25^+/−^ FoxP3^−^ non‐regulatory T cells in sdLNs of vehicle (ethanol, ETOH) *versus* vitamin D3 (VIT D)‐treated mice on day 3, day 5 and day 10 of treatment. Data are representative of two to three independent experiments and were analysed with a Student\'s *t*‐test or a Mann--Whitney *U*‐test, *n* = 4--14. n.s. not significant.](JCMM-20-930-g001){#jcmm12806-fig-0001}

T~regs~ display an activated phenotype in AD‐like inflammation {#jcmm12806-sec-0012}
--------------------------------------------------------------

To better characterize the CD4^+^ CD25^+^ FoxP3^+^ T~reg~ population in the VitD AD model, we measured the expression of various surface markers which are involved in T~reg~ function in mice with overt AD symptoms, i.e. on day 10 of treatment. Percentages of CD4^+^ CD25^+^ FoxP3^+^ T~regs~ expressing ICOS, CTLA‐4 and GARP at their cell surface were increased in sdLNs of mice with AD when compared to controls (Fig. [2](#jcmm12806-fig-0002){ref-type="fig"}A and B). Hence, peripheral activated T~regs~ are observed in AD‐like inflammation.

![Regulatory T cells are activated in murine AD‐like inflammation. Expression of ICOS (**A**), CTLA‐4 and GARP (**B**) at the cell surface of CD4^+^ FoxP3^+^ T~regs~ in sdLNs of ETOH *versus* VIT D‐treated mice on day 10 of treatment. Data are representative of one independent experiment and were analysed with a Student\'s *t*‐test or a Mann--Whitney *U*‐test, *n* = 4--6.](JCMM-20-930-g002){#jcmm12806-fig-0002}

LCs are the first DC subset to emigrate to sdLNs to potentially expand T~regs~ in AD {#jcmm12806-sec-0013}
------------------------------------------------------------------------------------

Earlier work has demonstrated that epidermal TSLP is overexpressed after topical treatment with the VitD analogue MC903 for 4 days [4](#jcmm12806-bib-0004){ref-type="ref"}. As opposed to dermal DCs, LCs acquire an activated phenotype in the skin after MC903 treatment and increased migration to sdLNs [4](#jcmm12806-bib-0004){ref-type="ref"}. These findings suggested that the activation of LCs may be associated with a biased Th2 response prior to the development of clinical signs of AD [4](#jcmm12806-bib-0004){ref-type="ref"}. On the other hand, activation and migration of LCs might also contribute to increased T~reg~ expansion in early AD. We therefore analysed total numbers of CD4^+^ CD25^+^ FoxP3^+^ T~regs~, LCs, Langerin^+^ and Langerin^−^ dermal DCs in sdLNs on days 0, 3 and 5 of topical VitD treatment. Numbers of CD4^+^ CD25^+^ FoxP3^+^ T~regs~ started to significantly increase in sdLNs as early as on day 3 (Fig. S1A), similar to emigrated LCs (Fig. S1B). Numbers of Langerin^+^ and Langerin^−^ dermal DCs and other DCs were not altered on day 3, but started to increase on day 5 (Fig. S1C--E), according to the literature [4](#jcmm12806-bib-0004){ref-type="ref"}, [26](#jcmm12806-bib-0026){ref-type="ref"}, [27](#jcmm12806-bib-0027){ref-type="ref"}. Taken together, our results establish that, in the VitD AD model, LCs are the first skin DC subset to reach the sdLNs, which coincides with the beginning of T~reg~ expansion. It was previously reported that VitD directly induces T~regs~ *in vitro* [28](#jcmm12806-bib-0028){ref-type="ref"}, challenging the requirement of skin‐derived DCs in the development of T~regs~ after topical application of VitD. To address this issue, we removed the application sites (ears) 4 hrs after a single topical application of vehicle or VitD (3 nmol/ear) to prevent any skin DC migration [29](#jcmm12806-bib-0029){ref-type="ref"}. As depicted in Figure S1, removal of the application sites prevented the increase of both T~regs~ (Fig. S1F) and DCs (Fig. S1G) in sdLNs of VitD‐treated as compared to vehicle‐treated mice. We verified that one‐time application of 3 nmol VitD per ear elicits the same effects on the numbers of various DC subsets and T~regs~ in sdLNs than a daily treatment with 1 nmol VitD for 3 days (data not shown). Therefore, expansion of CD4^+^ CD25^+^ FoxP3^+^ T~regs~ is not because of a direct effect of VitD in this mouse model of early AD, but instead requires the migration of skin‐derived DCs to sdLNs.

To further assess the tolerogenic function of skin DCs, we topically applied VitD to mice deficient for Langerin^+^ DCs, including LCs (Fig. S2). Numbers of CD4^+^ CD25^+^ FoxP3^+^ T~regs~ in sdLNs were increased on days 5 and 10 in VitD‐treated mice depleted of Langerin^+^ DCs as compared to vehicle‐treated controls (Fig. S3A and B). Therefore, the overall induction of T~regs~ might be initially dependent on LCs reaching firstly the sdLNs, whereas later on, other skin‐derived DC subsets contribute to this expansion.

Thymus‐derived T~regs~ are enhanced in AD {#jcmm12806-sec-0014}
-----------------------------------------

Helios, an Ikaros transcription factor preferentially expressed in human and mouse CD4^+^ FoxP3^+^ T~regs~, was shown to allow discrimination between thymus‐derived and peripherally induced T~regs~ [30](#jcmm12806-bib-0030){ref-type="ref"}, [31](#jcmm12806-bib-0031){ref-type="ref"}. In VitD‐induced AD‐like inflammation, the percentages of thymus‐derived (Helios^+^) T~regs~ were enhanced, whereas peripheral (Helios^−^) T~regs~ were reduced in sdLNs on day 10 of topical VitD treatment (Fig. [3](#jcmm12806-fig-0003){ref-type="fig"}A). Accordingly, thymus‐derived T~regs~ displayed higher absolute numbers (Fig. [3](#jcmm12806-fig-0003){ref-type="fig"}B). Kinetic analysis revealed a predominant expansion of thymus‐derived T~regs~ in sdLNs of mice as early as day 5 of topical VitD treatment (Fig. [4](#jcmm12806-fig-0004){ref-type="fig"}). Thus, our results indicate an early imbalance of the T~reg~ compartment towards predominating thymus‐derived T~regs~ in AD. Intriguingly, percentages of thymus‐derived T~regs~ failed to increase after depletion of Langerin^+^ DCs in mouse skin at day 5 of VitD‐treatment (Fig. [5](#jcmm12806-fig-0005){ref-type="fig"}). To identify the molecules providing the tolerogenic function to DCs, we screened for expression of various costimulatory and co‐inhibitory molecules, without identifying significant changes in the expression of PD‐L1, ICOS‐L, GITR‐L and IDO by VitD‐exposed DCs (data not shown). Moreover, we detected only trace amounts of IL‐10 production by skin‐derived DCs in our experiments (data not shown). Thus, thymus‐derived T~regs~ are increased in the VitD AD mouse model and Langerin^+^ DCs are required for the early expansion of thymus‐derived T~regs~ in AD, *via* a still elusive mechanism.

![Thymus‐derived regulatory T cells are increased in murine AD‐like inflammation. Percentages (**A**) and numbers (**B**) of thymus‐derived (Helios^+^) and peripherally derived (Helios^−^) regulatory T cells (CD4^+^ (CD25^+^) FoxP3^+^) in sdLNs of ETOH *versus* VIT D‐treated mice on day 10 of treatment. Data are representative of two independent experiments and were analysed with a Student\'s *t*‐test or a Mann--Whitney *U*‐test, *n* = 10--12.](JCMM-20-930-g003){#jcmm12806-fig-0003}

![Thymus‐derived regulatory T cells expand in murine AD‐like inflammation. Percentages (**A** and **C**) and numbers (**B** and **D**) of thymus‐derived (Helios^+^) and peripherally derived (Helios^−^) regulatory T cells (CD4^+^ (CD25^+^) FoxP3^+^) in sdLNs of ETOH *versus* VIT D‐treated mice on day 0, day 3, day 5 and day 10 of treatment. Data are representative of two to three independent experiments and were analysed with a Student\'s *t*‐test or a Mann--Whitney *U*‐test, *n* = 3--12. n.s. not significant.](JCMM-20-930-g004){#jcmm12806-fig-0004}

![Langerin^+^ dendritic cells expand thymus‐derived regulatory T cells in murine AD‐like inflammation. Percentages of thymus‐derived (Helios^+^) and peripherally derived (Helios^−^) (CD4^+^ CD25^+^ FoxP3^+^) T~regs~ in sdLNs from Langerin‐DTR mice, injected with PBS (+ Langerin^+^ DC) (**A**) or diphtheria toxin (− Langerin^+^ DC) (**B**), at day 5 of treatment. (**C**) Histograms showing all results. Data are representative of three independent experiments and were analysed with a Student\'s *t*‐test, *n* = 7--8. n.s. not significant.](JCMM-20-930-g005){#jcmm12806-fig-0005}

Thymus‐derived T~regs~ exhibit a Th2‐like phenotype in AD {#jcmm12806-sec-0015}
---------------------------------------------------------

We first measured the percentages of overall T~regs~ producing IL‐10 and IL‐13 in the VitD model of AD. T~regs~ isolated from AD mice (day 10 of treatment) produced larger amounts of both IL‐10 and IL‐13 than T~regs~ isolated from healthy controls, regardless of the presence of Langerin^+^ DCs (Fig. S3C and D). In contrast, the production of IL‐13 but not of IL‐10 by T~regs~ was significantly increased earlier during the development of AD, i.e. 5 days after the start of VitD treatment (Fig. [6](#jcmm12806-fig-0006){ref-type="fig"}A and B). Depletion of Langerin^+^ DCs did not alter the production of IL‐13 (Fig. [6](#jcmm12806-fig-0006){ref-type="fig"}B), but increased the secretion of IL‐10 by T~regs~ at early time‐points (Fig. [6](#jcmm12806-fig-0006){ref-type="fig"}A). Moreover, the production of IL‐13 was more strongly induced in T~regs~ than in CD4^+^ effector T cells in VitD‐induced early and overt AD (Fig. S4). To further dissect the production of cytokines within the T~reg~ compartment, we measured percentages of thymus‐ and peripherally derived T~regs~ producing IL‐10 and IL‐13. Thymus‐derived T~regs~ were identified as the main source of IL‐10 and IL‐13 (Fig. [6](#jcmm12806-fig-0006){ref-type="fig"}C--E). Notably, we observed similar numbers of thymus‐derived T~regs~ and effector T cells producing IL‐13 in the VitD AD model (Fig. [6](#jcmm12806-fig-0006){ref-type="fig"}F). Moreover, both numbers of thymus‐derived T~regs~ and effector T cells producing IL‐13 were higher than numbers of peripherally derived T~regs~. These findings emphasize the potential role of thymus‐derived Th2‐polarized T~regs~ in driving the pathogenic events leading to or sustaining AD and suggest that peripherally derived T~regs~ are small contributors to the overall Th2 cytokine production in VitD AD model (Fig. [6](#jcmm12806-fig-0006){ref-type="fig"}D and F). Furthermore, depletion of Langerin^+^ DCs did not alter the production of cytokines by thymus‐derived T~regs~ in the VitD model of AD (Fig. [6](#jcmm12806-fig-0006){ref-type="fig"}C and D). In conclusion, we identified activated, IL‐10‐producing thymus‐derived T~regs~, concomitantly exhibiting a Th2‐like phenotype in the VitD model of AD.

![Langerin^+^ dendritic cells are dispensable for cytokine‐producing phenotype of thymus‐derived regulatory T cells in murine AD‐like inflammation. Production of IL‐10 (**A**) and IL‐13 (**B**) by overall CD4^+^ FoxP3^+^ T~regs~ and production of IL‐10 (**C**) and IL‐13 (**D**) by thymus‐ and peripherally derived (CD4^+^ FoxP3^+^) T~regs~ in sdLNs from ETOH *versus* VIT D‐treated Langerin‐DTR mice, injected with PBS (+ Langerin^+^ DC) or diphtheria toxin (− Langerin^+^ DC), at day 5 of treatment. Percentages of effector T cells (**E**) and numbers of effector T cells, thymus‐ and peripherally derived T~regs~ (**F**) producing IL‐13 in sdLNs of ETOH or VIT D‐treated mice, at day 5 of treatment. Data are representative of one to three independent experiments and were analysed with a Student\'s *t*‐test, *n* = 6--8. n.s. not significant.](JCMM-20-930-g006){#jcmm12806-fig-0006}

Discussion {#jcmm12806-sec-0016}
==========

In this study we discovered higher numbers of overall T~regs~ with a specific expansion of thymus‐derived T~regs~ in mice with AD. Furthermore, our results indicate that AD is associated with the expansion of thymus‐derived T~regs~ exhibiting a Th2 phenotype and that LCs seem to be responsible for this biased T~reg~ differentiation. However, other cells or factors from the microenvironment in sdLNs might also contribute to shaping the unusual cytokine profile of thymus‐derived T~regs~. Irrespectively, our data strongly suggest that Th2‐like T~regs~ actively contribute to the development of AD [32](#jcmm12806-bib-0032){ref-type="ref"}.

Several groups reported increased T~regs~ in the peripheral blood [13](#jcmm12806-bib-0013){ref-type="ref"}, [14](#jcmm12806-bib-0014){ref-type="ref"}, [15](#jcmm12806-bib-0015){ref-type="ref"}, [16](#jcmm12806-bib-0016){ref-type="ref"} and skin lesions [10](#jcmm12806-bib-0010){ref-type="ref"} of AD patients, whereas others did not [10](#jcmm12806-bib-0010){ref-type="ref"}, [11](#jcmm12806-bib-0011){ref-type="ref"}, [12](#jcmm12806-bib-0012){ref-type="ref"}, [18](#jcmm12806-bib-0018){ref-type="ref"}. In support of the former, we here report increased numbers of CD4^+^ CD25^+^ FoxP3^+^ T~regs~ in sdLNs of mice at different disease stages of AD development (Fig. [1](#jcmm12806-fig-0001){ref-type="fig"}). The T‐cell‐specific costimulatory molecule ICOS is up‐regulated after cell activation and binding to its ligand (ICOS‐L). This step is essential for T~reg~ survival, proliferation and memory rather than for their activation [33](#jcmm12806-bib-0033){ref-type="ref"}. Indeed, reduced numbers of CD4^+^ FoxP3^+^ T~regs~ have been observed in ICOS knockout mice in the steady‐state and upon immunization [34](#jcmm12806-bib-0034){ref-type="ref"}. CTLA‐4 is a CD28 homologue that is up‐regulated after activation of effector T cells and T~regs~. It is associated with T~reg~ suppressive function, although this remains controversial [35](#jcmm12806-bib-0035){ref-type="ref"}. GARP (or LRRC32), a T~reg~‐specific activation marker, is part of the receptor for latency‐associated peptide/latent transforming growth factor‐β complex [36](#jcmm12806-bib-0036){ref-type="ref"}. In the VitD mouse model of AD, percentages of T~regs~ expressing ICOS (Fig. [2](#jcmm12806-fig-0002){ref-type="fig"}A), CTLA‐4 and GARP (Fig. [2](#jcmm12806-fig-0002){ref-type="fig"}B) and producing IL‐10 (Fig. [6](#jcmm12806-fig-0006){ref-type="fig"}A and C, Fig. S3C) were increased, indicating an activated phenotype. However, expansion of activated T~regs~ in VitD AD‐like inflammation is unable to counteract ongoing AD. A similar situation is highly probable in AD patients [10](#jcmm12806-bib-0010){ref-type="ref"}, [13](#jcmm12806-bib-0013){ref-type="ref"}, [14](#jcmm12806-bib-0014){ref-type="ref"}, [15](#jcmm12806-bib-0015){ref-type="ref"}, [16](#jcmm12806-bib-0016){ref-type="ref"}.

T~regs~ can be divided into two subcategories, namely thymus‐derived and peripherally induced T~regs~. While Helios is expressed in all CD4^+^ CD8^−^ FoxP3^+^ mouse thymocytes [30](#jcmm12806-bib-0030){ref-type="ref"}, neuropilin discriminates thymic T~regs~ from peripheral T~regs~ only in the steady‐state [37](#jcmm12806-bib-0037){ref-type="ref"}. Therefore, Helios is currently the most discriminative marker for thymus‐derived T~regs~ [30](#jcmm12806-bib-0030){ref-type="ref"}. We found that the ratio of thymus‐derived (Helios^+^) T~regs~ over peripherally derived (Helios^−^) T~regs~ was increased in sdLNs during AD‐like inflammation (Fig. [3](#jcmm12806-fig-0003){ref-type="fig"}), with enhanced expansion of thymus‐derived (Helios^+^) T~regs~ starting early in the development of the disease (Fig. [4](#jcmm12806-fig-0004){ref-type="fig"}). Thymus‐derived T~regs~ are involved in self‐tolerance and were shown to be activated by microbes [32](#jcmm12806-bib-0032){ref-type="ref"}. Moreover, they are important for the control of Th1 immune responses [38](#jcmm12806-bib-0038){ref-type="ref"}. Thus, thymic T~regs~ might be less efficient at counteracting Th2‐related diseases such as AD when compared to peripherally induced T~regs~.

The T~reg~ population is heterogeneous. Indeed, T~regs~ can acquire alternative effector or hybrid fates, associated with promotion rather than inhibition of inflammation under certain conditions [32](#jcmm12806-bib-0032){ref-type="ref"}. Accordingly, increased production of IL‐5 and IL‐13 has been described in skin‐homing T~regs~ of AD patients [12](#jcmm12806-bib-0012){ref-type="ref"}, [14](#jcmm12806-bib-0014){ref-type="ref"}. High expression of GATA3, as observed in T~regs~ located at barrier sites such as the skin and gut [39](#jcmm12806-bib-0039){ref-type="ref"}, might enable T~regs~ to produce Th2 cytokines. In our VitD AD model, we found increased percentages of IL‐13‐producing T~regs~ in sdLNs (Fig. [6](#jcmm12806-fig-0006){ref-type="fig"}B and D, Figs S3D and S4), similar to Th2 T~regs~ in the skin of AD patients [12](#jcmm12806-bib-0012){ref-type="ref"}, [14](#jcmm12806-bib-0014){ref-type="ref"}. This might potentially confer a pro‐ rather than an anti‐inflammatory phenotype to T~regs~ in AD.

When we analysed the cytokine production by T~regs~ more thoroughly, we found that thymus‐derived T~regs~ were the main source of IL‐10 and IL‐13 in the VitD AD model (Fig. [6](#jcmm12806-fig-0006){ref-type="fig"}C--E). Therefore, we demonstrate here for the first time that expansion of thymus‐derived T~regs~ exhibiting a Th2‐like phenotype is promoted in AD. In fact, the numbers of thymic T~regs~ secreting IL‐13 were similar to the numbers of effector T cells producing IL‐13 (Fig. [6](#jcmm12806-fig-0006){ref-type="fig"}F) and the percentages of thymus‐derived T~regs~ secreting IL‐13 were significantly increased compared to effector T cells (Fig. [6](#jcmm12806-fig-0006){ref-type="fig"}D and E). This strongly suggests a pathogenic role of thymus‐derived Th2‐polarized T~regs~ in AD. Indeed, these T~regs~ might exert poor immunosuppressive properties despite their capacity to produce IL‐10 and consequently contribute to the development of AD‐like inflammation. It would be of particular interest to test this hypothesis by assessing the overall immunosuppressive capacity of these Th2 T~regs~. Unfortunately, due to the nuclear localization of Helios, the lack of Helios‐EGFP mice, and the missing specificity of neuropilin as a surface marker during inflammation, it is not possible to purify Th2 thymus‐derived T~regs~ for further *in vitro* immunosuppressive assays.

Dendritic cells are antigen‐presenting cells regulating immunity and tolerance, respectively, by priming effector T cells and expanding T~regs~ [40](#jcmm12806-bib-0040){ref-type="ref"}. In the VitD AD model, T~reg~ expansion in sdLNs required the presence of skin‐derived DCs (Fig. S1F and G). The time course of T~reg~ induction revealed that, unexpectedly, LCs are the first cutaneous DC subset to reach sdLNs in our experimental setup (Fig. S1A--E). VitD‐induced production of TSLP by keratinocytes might primarily trigger LCs, whereas dermal DCs migrate to sdLNs more quickly after skin immunization with DNFB [4](#jcmm12806-bib-0004){ref-type="ref"}, [41](#jcmm12806-bib-0041){ref-type="ref"}. Previous results established that LCs promote T~reg~ proliferation upon RANK signalling [42](#jcmm12806-bib-0042){ref-type="ref"}. However, depletion of LCs and Langerin^+^ dermal DCs did not affect the size of the overall CD4^+^ CD25^+^ FoxP3^+^ T~reg~ population in sdLNs of VitD‐induced AD mice (Fig. S3A and B) but specifically abolished the induction of thymus‐derived T~regs~ (Fig. [5](#jcmm12806-fig-0005){ref-type="fig"}). Moreover, depletion of LCs and Langerin^+^ dermal DCs did not affect the production of IL‐13 by T~regs~, regardless of Helios expression (Fig. [6](#jcmm12806-fig-0006){ref-type="fig"}B and D, Fig. S3D). Thymus‐derived T~regs~ are involved in antimicrobial responses [32](#jcmm12806-bib-0032){ref-type="ref"} and LCs are a privileged DC subset sensing microbe‐derived antigens in AD [43](#jcmm12806-bib-0043){ref-type="ref"}. Thus, the expansion of thymus‐derived T~regs~ might be attributed to LCs, while their cytokine production might rather be determined by other cells or factors within the microenvironment of the sdLNs. Langerhans cell‐derived IL‐10 can promote T~reg~ expansion [44](#jcmm12806-bib-0044){ref-type="ref"}, [45](#jcmm12806-bib-0045){ref-type="ref"}, but in our experiments, IL‐10 was not detectable in skin‐derived DCs following VitD treatment (data not shown). Furthermore, expression of PD‐L1, ICOS L, GITR L and IDO by skin‐derived DCs might only have a supporting role in T~reg~ expansion in the VitD AD mouse model (data not shown). Thus, the question how LCs or other DCs promote the expansion of T~regs~ or otherwise impact on their phenotype remains unanswered.

In summary, our work represents the first study demonstrating a preferential expansion of activated CD4^+^ CD25^+^ FoxP3^+^ thymus‐derived T~regs~ exhibiting a Th2 phenotype in a mouse model of AD. Furthermore, differentiation of thymus‐derived T~regs~ seems to depend on LCs, while their cytokine profile might rather be determined by DC phenotype and their microenvironment. Hence, T~regs~ in AD might contribute to the disease rather than playing their role of immunosuppressive cells and thus might represent potential new therapeutic targets.
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**Figure S1** (A--E) Numbers of CD4^+^ CD25^+^ FoxP3^+^ T~regs~ (A) and DC (B--E) in sdLNs in mice treated with ETOH or VIT D.

**Figure S2** Depletion of Langerin‐expressing DCs in epidermis (A--D) and sdLNs (E--H) from Langerin‐DTR mice, topically treated with ETOH (A, B, E and F) or VIT D (C, D, G and H), after intraperitoneal injection of PBS (A, C, E and G) or DT (B, D, F and H) on day −2, day +2, day +6 and day +8.

**Figure S3** (A and B) Numbers of T~regs~ in sdLNs from Langerin‐DTR mice, injected with PBS (+ Langerin^+^ DC) or diphtheria toxin (− Langerin^+^ DC), at day 5 (A) and day 10 (B) of treatment.

**Figure S4** Percentages of IL‐13‐producing effector and total T~regs~ in sdLNs of ETOH or VIT D‐treated mice at day 5 (A) and day 10 (B) of treatment.
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